Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

582 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dienstmann R, Oaknin A. Rodriguez-Freixinos V, et al. Among authors: ponce j. Gynecol Oncol. 2019 Feb;152(2):270-277. doi: 10.1016/j.ygyno.2018.11.036. Epub 2018 Dec 12. Gynecol Oncol. 2019. PMID: 30551885
Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].
Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gomez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Roman S, Ponce J, Melendez C, Carballas E, Dienstmann R, Oaknin A. Rodriguez-Freixinos V, et al. Among authors: ponce j. Gynecol Oncol. 2020 Jan;156(1):262. doi: 10.1016/j.ygyno.2019.10.020. Epub 2019 Nov 16. Gynecol Oncol. 2020. PMID: 31744639 No abstract available.
Predictive factors for irresectability in advanced ovarian cancer.
Martínez-Saíd H, Rincón DG, Montes de Oca MM, Ruiz GC, Ponce JL, López-Graniel CM. Martínez-Saíd H, et al. Among authors: ponce jl. Int J Gynecol Cancer. 2004 May-Jun;14(3):423-30. doi: 10.1111/j.1048-891x.2004.014301.x. Int J Gynecol Cancer. 2004. PMID: 15228414
Basic Science and Pathogenesis.
Kavanagh T, Ponce J, Thierry M, Ueberheide B, Wisniewski T, Drummond E. Kavanagh T, et al. Among authors: ponce j. Alzheimers Dement. 2024 Dec;20 Suppl 1:e090560. doi: 10.1002/alz.090560. Alzheimers Dement. 2024. PMID: 39751623
Basic Science and Pathogenesis.
Thierry M, Ponce J, Ariza MM, Askenazi M, Faustin A, Leitner D, Pires G, Kanshin E, Drummond E, Ueberheide B, Wisniewski T. Thierry M, et al. Among authors: ponce j. Alzheimers Dement. 2024 Dec;20 Suppl 1:e091601. doi: 10.1002/alz.091601. Alzheimers Dement. 2024. PMID: 39750893
International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).
Cohen RV, Busetto L, Levinson R, Le Roux CW, Salminen P, Prager G; International Consensus on the Role of Obesity Management Medications in the Context of Metabolic Bariatric Surgery. Cohen RV, et al. Br J Surg. 2024 Nov 27;111(12):znae283. doi: 10.1093/bjs/znae283. Br J Surg. 2024. PMID: 39612579 No abstract available.
High CTLA-4 gene expression is an independent good prognosis factor in breast cancer patients, especially in the HER2-enriched subtype.
Montoyo-Pujol YG, Ponce JJ, Delgado-García S, Martín TA, Ballester H, Castellón-Molla E, Ramos-Montoya A, Lozano-Cubo I, Sempere-Ortells JM, Peiró G. Montoyo-Pujol YG, et al. Among authors: ponce jj. Cancer Cell Int. 2024 Nov 10;24(1):371. doi: 10.1186/s12935-024-03554-4. Cancer Cell Int. 2024. PMID: 39523362 Free PMC article.
582 results